These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 39009505)

  • 1. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
    Xiao Z; Cao J; Wu S; Zhou T; Li C; Duan J; Yang Z; Xu F
    CNS Neurosci Ther; 2024 Jul; 30(7):e14862. PubMed ID: 39009505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.
    Lin W; Zeng Y; Weng L; Yang J; Zhuang W
    BMC Pharmacol Toxicol; 2024 Aug; 25(1):47. PubMed ID: 39123221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation.
    Hua M; Xiong F; Chong S; Zhang Z; Liu Q; Hou J; Zhang Z; Gu Z; Cui X; Cui Y; Xu L; Xiang Q
    Cancer Treat Rev; 2024 Nov; 130():102827. PubMed ID: 39278067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting system.
    Yan Y; Wu B; Wang L
    Expert Opin Drug Saf; 2024 Sep; 23(9):1191-1198. PubMed ID: 38482864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; La Placa M; Ardizzoni A; Zamagni C; Poluzzi E; De Ponti F
    Am J Clin Dermatol; 2022 Mar; 23(2):247-255. PubMed ID: 34699032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.
    Ren X; Yan C; Tian L; Cui X
    Int J Immunopathol Pharmacol; 2022; 36():3946320221145520. PubMed ID: 36565299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data.
    Yan MM; Wu SS; Qi YP; Li ZR; Zhang Q; Zhao H; Zhong MK; Qiu XY
    Expert Opin Drug Saf; 2022 Feb; 21(2):277-283. PubMed ID: 34581647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
    Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
    Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CDK4/6 inhibitors and drug-related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System.
    Go M; Noguchi Y; Masuda R; Asano H; Kimura M; Usami E; Yoshimura T
    Int J Cancer; 2024 Sep; 155(5):849-853. PubMed ID: 38619193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
    Ren X; Wang H; Deng L; Wang W; Wang Y
    Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
    Chen M; Huang Y; Jiang S; Ke C
    Lung Cancer; 2024 Oct; 196():107966. PubMed ID: 39342769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network.
    She Y; Guo Z; Zhai Q; Liu J; Du Q; Zhang Z
    Front Pharmacol; 2024; 15():1378090. PubMed ID: 38633610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
    Yang Q; Wang J; Wang M; Zhang S; He QQ
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):64. PubMed ID: 39267168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
    Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
    Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling the Cardiovascular Toxicities of CDK4/6 Inhibitors: A Real-World Pharmacovigilance Study.
    Kim JH
    Cancers (Basel); 2024 Aug; 16(16):. PubMed ID: 39199640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.